Transforming healthcare for people living with chronic conditions.
Introducing Kitea: the world's most accurate implantable sensor for heart failure and hydrocephalus.
Pressure-guided management of chronic disease.
Kitea enables early intervention and delivers better outcomes at every level, through the next generation of micro-implantable devices.
26 million people worldwide are in heart failure.
A complex disease, heart failure carries an annual global economic burden of US $108 billion.
Today's treatment barriers are failing patients.
Hospitalisation for heart failure often occurs when the patient presents with symptoms of clinical congestion. By this stage, patients may already be in early-stage heart failure.
Treatment is reactive
Assessment of deterioration is complex and expensive
Do not conform to schedules
Deterioration in cardiac function occurs randomly
Significant risks
Delayed treatment can lead to a cascade of disease progression
Requires hospital admission
Patients spend valuable time in hospital away from family
Heart failure: by the numbers
How it works
The Kitea system eliminates guesswork by enabling pressure monitoring at home and in hospital, for the first time.
Enable
Device is implanted during a simple procedure, designed for long-term use
Measure
Take pressure measurements in hospital or at home, and track symptoms
Manage
Physicians monitor measurements and set thresholds for portal notifications
Resolve
Physicians make informed decisions based on real pressure values
Hydrocephalus: from reactive to proactive care.
Caused by a buildup of excess fluid in the brain, hydrocephalus is a serious, lifelong condition.
The condition disproportionately affects children, and it is generally fatal without treatment. The main treatment path places a shunt in the brain to drain excess fluid and prevent a rise in pressure.
Shunt failure is common
Highest failure rate of any implanted medical device
Symptoms are confusing
Shunt failure can mimic common illnesses
Significant risks
Increase in intracranial pressure can be life threatening
Requires hospital admission
Assessment of failure is complex and expensive
A better way with Kitea.
Hydrocephalus: by the numbers
Improving outcomes at every level.
For patients
-
Reduced inequity in healthcare access
-
Monitor symptoms any time, any place
-
Early detection, less time in hospital
For hospitals
-
Estimated 30% reduction in costs
-
Fewer CT, MRI and other imaging procedures
-
Better clinical outcomes
For payers
-
Significant reduction in insurance costs
-
Better outcomes for patients
-
Reimbursement codes available for remote monitoring
Contact the team.
Sources: Heart failure
1. Malik A, Brito D, Vaqar S, et al. Congestive Heart Failure. [Updated 2022 Nov 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan
2. Urbich, M., Globe, G., Pantiri, K. et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics 38, 1219–1236 (2020).
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013; 6:606–619.
4. Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMSHF). Eur J Heart Fail 2020;22:1891–901.
5. Ambulatory haemodynamic-guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort. Dauw J, Sokolski M, Middleton JT, Nijst P, Dupont M, Forouzan O, Rothman AMK, Ruschitzka F, Flammer AJ, Mullens W.ESC Heart Fail. 2022 Dec;9(6):3858-3867. doi: 10.1002/ehf2.14056. Epub 2022 Aug 2.
Sources: Hydrocephalus
1. Hydrocephalus Association; About Hydrocephalus
2. Simon TD, Riva-Cambrin J, Srivastava R, Bratton SL, Dean JM, Kestle JR; Hydrocephalus Clinical Research Network. Hospital care for children with hydrocephalus in the United States: utilization, charges, comorbidities, and deaths. J Neurosurg Pediatr. 2008 Feb;1(2):131-7.
3. Reddy GK, Bollam P, Caldito G. Long-Term Outcomes of Ventriculoperitoneal Shunt Surgery in Patients with Hydrocephalus. World Neurosurgery. 2014;81(2):404-10.
4. Chern JJ, Macias CG, Jea A, Curry DJ, Luerssen TG, Whitehead WE. Effectiveness of a clinical pathway for patients with cerebrospinal fluid shunt malfunction. Journal of Neurosurgery: Pediatrics. 2010;6(4):318-24
5. Naftel RP, Tubergen E, Shannon CN, Gran KA, Vance EH, Oakes WJ, et al. Parental recognition of shunt failure: a prospective single-institution study. Journal of Neurosurgery: Pediatrics. 2012;9(4):363-71.
6. Barber, J.M., et al., Telemetric intra-cranial pressure monitoring: clinical and financial considerations. British Journal of Neurosurgery, 2017. 31(3): p. 300-306.